Sepsis and septic shock


State-of-the-art therapy for patients with endotoxic septic shock

Septic shock is associated with an unacceptable high mortality and a significant economic burden to the sanitary system. Endotoxin is the most potent trigger of the septic cascade and during the progress of sepsis, endotoxin levels can increase up to 1000 fold, even when cultures result negative for Gram-negative bacteria.

Toraymyxin®  Polymyxin B hemoperfusion therapy – from Toray Medical Ltd. (Japan), is the state-of-the-art therapy for endotoxin removal in septic shock patients. More than 200,000 patients have been treated with this innovative therapy and more than 400 peer-reviewed articles have been published, demonstrating the beneficial effects on hemodynamics, organ function and mortality. Toraymyxin® is now available in two versions: PMX-20R device for patients with adult body volume and PMX-05R device for patients with reduced body volume.

EAA™Endotoxin Activity Assay – is the only FDA approved diagnostic assay to detect endotoxin activity in human whole blood. The EAA™ diagnostic test is performed in less than 30 minutes. EAA™ is the diagnostic assay to identify patients with endotoxic septic shock.


Chronic kidney disease


A personalized therapy based on the individual needs of each patient


Acute kidney injury


HEMOFEELTM is a new membrane for continuous renal support made of polymethylmethacrylate, a highly hemo- and biocompatible material designed by TORAY – a global leader in advanced materials.

Focus on


SMART WEBINAR – Mini-Invasive CO2 Removal: a Concrete Answer for Reducing the Ventilation Burden

On Tuesday 30 November at 16.30 CET in collaboration with SMART (Smart Meeting Anesthesia Resuscitation Intensive Care) we are supporting the webinar entitled “Mini-Invasive CO2 Removal: a Concrete Answer for Reducing the Ventilation Burden”.


Endotoxemia in critically ill COVID-19 patients – from pathophysiology to advanced targeted complementary therapies

Critically ill COVID-19 patients present a dysregulated host response to infection caused by the primary viral SARS-CoV-2 infection and/or subsequent bacterial superinfections. This can lead to conditions of unresponsive septic shock with high fatality rate.
Here we review the recent literature on COVID-19 pathophysiology and the application of Polymyxin B hemoperfusion (PMX-HP) for the management of critically ill COVID-19 patients with endotoxic shock



The joint congress EACTAIC-ICCVA “Shaping the future of Cardiovascular and Thoracic Anesthesia and Intensive Care” will be held virtually from 27 to 29 October 2021. Estor supports a webinar entitled “Endotoxemia During and After Cardiac Surgery: Possible Targeted Solutions”.